AR079050A1 - Compuestos benzoimidazolicos y sus usos - Google Patents

Compuestos benzoimidazolicos y sus usos

Info

Publication number
AR079050A1
AR079050A1 ARP100104240A ARP100104240A AR079050A1 AR 079050 A1 AR079050 A1 AR 079050A1 AR P100104240 A ARP100104240 A AR P100104240A AR P100104240 A ARP100104240 A AR P100104240A AR 079050 A1 AR079050 A1 AR 079050A1
Authority
AR
Argentina
Prior art keywords
compound
formula
benzoimidazolic
compounds
salt
Prior art date
Application number
ARP100104240A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR079050A1 publication Critical patent/AR079050A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP100104240A 2009-11-18 2010-11-17 Compuestos benzoimidazolicos y sus usos AR079050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18

Publications (1)

Publication Number Publication Date
AR079050A1 true AR079050A1 (es) 2011-12-21

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104240A AR079050A1 (es) 2009-11-18 2010-11-17 Compuestos benzoimidazolicos y sus usos

Country Status (16)

Country Link
US (1) US8530467B2 (enExample)
EP (1) EP2501697B1 (enExample)
JP (1) JP5657018B2 (enExample)
KR (1) KR20120113709A (enExample)
CN (1) CN102741245B (enExample)
AR (1) AR079050A1 (enExample)
AU (1) AU2010322478B2 (enExample)
BR (1) BR112012011518B8 (enExample)
CA (1) CA2777746C (enExample)
ES (1) ES2442797T3 (enExample)
IN (1) IN2012DN03391A (enExample)
MX (1) MX2012005329A (enExample)
RU (1) RU2542582C2 (enExample)
TW (1) TW201121957A (enExample)
UY (1) UY33037A (enExample)
WO (1) WO2011062550A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
US9598409B2 (en) * 2013-01-31 2017-03-21 Neomed Institute Imidazopyridine compounds and uses thereof
CN105992761A (zh) * 2013-12-20 2016-10-05 盐野义制药株式会社 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
US10195198B2 (en) 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
SG11202106706TA (en) * 2018-12-29 2021-07-29 Wuhan Ll Science And Technology Development Co Ltd Heterocyclic compound intermediate, preparation method therefor and application thereof
EP3930722A4 (en) * 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
CN119039290A (zh) * 2020-02-14 2024-11-29 葛兰素史密斯克莱知识产权(第3号)有限公司 P2x3调节剂
JP2023536986A (ja) * 2020-08-13 2023-08-30 上海拓界生物医薬科技有限公司 ベンズイミダゾール誘導体、その調製方法及び医薬用途
TW202227458A (zh) * 2020-12-04 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 含有稠合三環的化合物及其醫藥用途
CN114478508A (zh) * 2021-12-31 2022-05-13 淮北师范大学 一种苯并咪唑化合物的结晶形式
CN118556054A (zh) * 2022-02-11 2024-08-27 江苏恒瑞医药股份有限公司 一种p2x3受体拮抗剂的结晶形式及其制备方法
WO2023151658A1 (zh) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 一种p2x3受体拮抗剂的可药用盐及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05708B1 (et) 1999-02-10 2014-04-15 Astrazeneca Ab Kinasoliini derivaat angiogeneesi inhibiitorina ja selle kasutamine
KR100763779B1 (ko) * 2000-01-17 2007-10-05 데이진 가부시키가이샤 벤즈이미다졸 유도체
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
ATE545644T1 (de) * 2004-09-24 2012-03-15 Astrazeneca Ab Benzimidazolderivate, diese enthaltende zusammensetzungen, herstellung davon und anwendungen davon i
TW200843756A (en) * 2007-03-02 2008-11-16 Schering Corp Benzimidazole derivatives and methods of use thereof
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2011502148A (ja) * 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのp2x3受容体アンタゴニスト

Also Published As

Publication number Publication date
BR112012011518B8 (pt) 2023-01-10
UY33037A (es) 2011-06-30
JP2013511517A (ja) 2013-04-04
CN102741245B (zh) 2014-11-05
ES2442797T3 (es) 2014-02-13
IN2012DN03391A (enExample) 2015-10-23
KR20120113709A (ko) 2012-10-15
CA2777746A1 (en) 2011-05-26
US8530467B2 (en) 2013-09-10
RU2542582C2 (ru) 2015-02-20
BR112012011518A2 (pt) 2016-06-28
JP5657018B2 (ja) 2015-01-21
CA2777746C (en) 2019-05-14
MX2012005329A (es) 2012-05-29
EP2501697A4 (en) 2013-04-24
US20120289504A1 (en) 2012-11-15
AU2010322478A1 (en) 2012-05-31
CN102741245A (zh) 2012-10-17
WO2011062550A1 (en) 2011-05-26
AU2010322478B2 (en) 2013-11-14
TW201121957A (en) 2011-07-01
EP2501697B1 (en) 2013-10-23
RU2012124268A (ru) 2013-12-27
EP2501697A1 (en) 2012-09-26
BR112012011518B1 (pt) 2020-03-10

Similar Documents

Publication Publication Date Title
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
UY32490A (es) Inhibidores de beta-secretasa
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
UY32062A (es) Inhibidores de beta-secretasa
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
CR11857A (es) Compuestos pirazolicos 436
CR10479A (es) Modulares bencimidazolicos de vr1
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
CO6761373A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
GT200600117A (es) Nuevos compuestos farmaceuticos
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii

Legal Events

Date Code Title Description
FB Suspension of granting procedure